XOMA Royalty (XOMA) Stock Price, News & Analysis

Company Overview

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways.

Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.

Key Stats

• Today's Range: $41.40 to $42.00
• 50-Day Range: $25.32 to $41.97
• 52-Week Range: $22.29 to $42.81
• Volume: 164,148 shs
• Average Volume: 373,301 shs
• Market Capitalization: $495.71 million
• P/E Ratio: 28.49
• Dividend Yield: N/A
• Price Target: $53.75
• Consensus Rating: Hold

XOMA Royalty Stock Analysis - MarketRank™

XOMA Royalty scored higher than 71% of companies evaluated by MarketBeat, and ranked 193rd out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

XOMA Royalty has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 2 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

XOMA Royalty has a consensus price target of $53.75, representing about 29.2% upside from its current price of $41.60.

Amount of Analyst Coverage

XOMA Royalty has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -26.60%

Earnings Growth

Earnings for XOMA Royalty are expected to decrease by -26.60% in the coming year, from $0.94 to $0.69 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of XOMA Royalty is 28.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.46.

Price to Earnings Ratio vs. Sector

The P/E ratio of XOMA Royalty is 28.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.28.

Price to Book Value per Share Ratio

XOMA Royalty has a P/B Ratio of 6.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.31% of the float of XOMA Royalty has been sold short.

Short Interest Ratio / Days to Cover

XOMA Royalty has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in XOMA Royalty has recently decreased by 12.16%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

XOMA Royalty does not currently pay a dividend.

Dividend Growth

XOMA Royalty does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: N/A

News Sentiment

XOMA Royalty has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for XOMA Royalty this week, compared to 4 articles on an average week.

Search Interest

7 people have searched for XOMA on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added XOMA Royalty to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, XOMA Royalty insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.90% of the stock of XOMA Royalty is held by insiders.

Percentage Held by Institutions

95.92% of the stock of XOMA Royalty is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XOMA Stock Analysis - Frequently Asked Questions

How have XOMA shares performed this year?

XOMA Royalty's stock was trading at $26.59 at the start of the year. Since then, XOMA stock has increased by 56.4% and is now trading at $41.60.

How were XOMA Royalty's earnings last quarter?

XOMA Royalty Corporation (NASDAQ:XOMA) posted its quarterly earnings results on Wednesday, March, 18th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.16. The biotechnology company had revenue of $13.76 million for the quarter, compared to the consensus estimate of $11.13 million. XOMA Royalty had a trailing twelve-month return on equity of 10.32% and a net margin of 45.75%.
Read the conference call transcript.

Who are XOMA Royalty's major shareholders?

Top institutional shareholders of XOMA Royalty include Bank of New York Mellon Corp (0.63%). Insiders that own company stock include Bvf Partners L P/Il, Owen Hughes, Thomas M Burns, Joseph M Limber and Bradley Sitko.
View institutional ownership trends.

How do I buy shares of XOMA Royalty?

Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of XOMA Royalty own?

Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA Royalty investors own include American Water Works (AWK), Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 3/18/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XOMA
• CIK: 791908
• Web: www.xoma.com
• Phone: (510) 204-7200
• Fax: 510-649-7571
• Employees: 10
• Year Founded: 1981

Price Target and Rating

• Average Price Target for XOMA Royalty: $53.75
• High Price Target: $76.00
• Low Price Target: $39.00
• Potential Upside/Downside: +29.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.46
• Trailing P/E Ratio: 28.49
• Forward P/E Ratio: 44.26
• P/E Growth: N/A
• Net Income: $31.71 million
• Net Margins: 45.75%
• Pretax Margin: 61.01%
• Return on Equity: 10.32%
• Return on Assets: 3.49%

Debt

• Debt-to-Equity Ratio: 1.15
• Current Ratio: 3.37
• Quick Ratio: 3.37

Sales & Book Value

• Annual Sales: $11.66 million
• Price / Sales: 42.51
• Cash Flow: $0.58 per share
• Price / Cash Flow: 71.98
• Book Value: $6.77 per share
• Price / Book: 6.14

Miscellaneous

• Outstanding Shares: 11,916,000
• Free Float: 10,855,000
• Market Cap: $495.71 million
• Optionable: Optionable
• Beta: 0.90